Biliary Concentration of Carbohydrate Antigen 19-9 and Cancer Antigen 125, Iron Metabolism Markers, and PIVKA-II Activity in Pancreatobiliary Tumors
Digestive Diseases · 12.12.2025 · 44 (1) · 73-84
DOI: 10.1159/000549784 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases, online erschienen am 12.12.2025. Verfasst von Paweł B Podgórski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: CA-19-9 Antigen, Pancreatic Neoplasms, Biomarkers, Tumor, Iron. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
Introduction
Biliary tract cancers (cholangiocarcinoma/gallbladder cancer [CCA/GCA]) and pancreatic cancers (PCs) are one of the most aggressive tumors with poor prognosis, frequently diagnosed at advanced stages. Current diagnostic methods are unsatisfactory. This study evaluated diagnostic yield of selected biliary biomarkers.
Methods
A prospective study enrolled 80 patients treated with endoscopic retrograde cholangiopancreatography (ERCP) because of choledocholithiasis (n = 50), CCA/GCA (n = 13), and PC (n = 17). Bile samples collected during ERCP were analyzed with electrochemiluminescence immunoassay for carbohydrate antigen 19-9 (CA19-9), PIVKA-II, osteocalcin, AFP, CA15-3, CEA and ferritin, chemiluminescent immunoassay for cancer antigen 125 (CA125), colorimetric analysis for iron and total iron-binding capacity (TIBC), as well as enzyme-linked immunosorbent assay for hepcidin.
Results
Several analyzed biomarkers demonstrated statistically significant differences in bile concentrations between patients with choledocholithiasis and malignant diseases. Particularly notable difference was observed for hepcidin and CA125. The biliary iron concentration and TIBC were inconclusive. PIVKA-II protein was confirmed as a reliable qualitative tumor marker. Attempts to detect osteocalcin, AFP, CA15-3, and CEA in bile failed due to concentrations being below the detectable threshold. No markers differentiated accurately the tumor type (p > 0.05).
Conclusion
CA125 and hepcidin as quantitative markers, along with PIVKA-II as a qualitative marker, demonstrate significant potential as biliary markers for distinguishing choledocholithiasis from biliary tract or PCs. Biliary iron, TIBC, and CA19-9 require further investigation to confirm their diagnostic yield.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
- Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, aprzybylkowski@wum.edu.pl.
- Department of Laboratory Medicine, Medical University of Warsaw, Warsaw, Poland.
Zitieren
APA
Podgórski, P. B., Przybyłkowski, A., Nehring, P., & Ciepiela, O. (2025). Biliary Concentration of Carbohydrate Antigen 19-9 and Cancer Antigen 125, Iron Metabolism Markers, and PIVKA-II Activity in Pancreatobiliary Tumors. Digestive Diseases, 44(1), 73-84. https://doi.org/10.1159/000549784
Vancouver
Podgórski PB, Przybyłkowski A, Nehring P, Ciepiela O. Biliary Concentration of Carbohydrate Antigen 19-9 and Cancer Antigen 125, Iron Metabolism Markers, and PIVKA-II Activity in Pancreatobiliary Tumors. Digestive Diseases. 2025;44(1):73-84. doi:10.1159/000549784
BibTeX
@article{Podgrski2025,
author = {Podgórski, Paweł B and Przybyłkowski, Adam and Nehring, Piotr and Ciepiela, Olga},
title = {Biliary Concentration of Carbohydrate Antigen 19-9 and Cancer Antigen 125, Iron Metabolism Markers, and PIVKA-II Activity in Pancreatobiliary Tumors},
journal = {Digestive Diseases},
year = {2025},
volume = {44},
number = {1},
pages = {73--84},
doi = {10.1159/000549784}
}
EUVIMED